The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
The initiative opens pathways for female students to pursue healthcare programs across 20+ top universities and colleges in India
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
Veteran pharmaceutical executive to relocate to Saudi Arabia and spearhead Cipla’s growth strategy across the Middle East region
Subscribe To Our Newsletter & Stay Updated
